We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
-$43.5M
Cap. Flow
+$1.54M
Cap. Flow %
0.14%
Top 10 Hldgs %
61.62%
Holding
73
New
4
Increased
21
Reduced
29
Closed
16
Avg Time Held Equity + Options
1.6 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.7 years
Top 10 Avg Time Held Equity only
1.1 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.9M
2
INSP icon
Inspire Medical Systems
INSP
+$25.6M
3
IMGN icon
Immunogen Inc
IMGN
+$14.9M
4
RVTY icon
Revvity
RVTY
+$14.5M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.8M
2
DHR icon
Danaher
DHR
+$16.2M
3
NTRA icon
Natera
NTRA
+$12M
4
AMRX icon
Amneal Pharmaceuticals
AMRX
+$11.2M
5
GSK icon
GSK
GSK
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.59%
2 Miscellaneous 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZIMV icon
26
DELISTED
ZimVie
ZIMV
$9.7M 0.85%
+546,444
New +$5.51M
2023 Q4
0 quarters
DHR icon
27
Danaher
DHR
$161B
$9.49M 0.83%
41,041
-76,027
-65% -$16.2M
2018 Q3
21 quarters
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$1.99B
$9.16M 0.8%
1,529,047
-950,056
-38% -$5.51M
2022 Q4
4 quarters
WAT icon
29
Waters Corp
WAT
$42.9B
$9.13M 0.8%
27,719
+4,595
+20% +$1.27M
2023 Q2
2 quarters
LQDA icon
30
Liquidia Corp
LQDA
$3.07B
$8.29M 0.73%
688,926
-706,528
-51% -$5.09M
2021 Q1
11 quarters
PBYI icon
31
Puma Biotechnology
PBYI
$507M
$7.34M 0.64%
1,695,021
+13,872
+0.8% +$46K
2021 Q3
9 quarters
CNC icon
32
Centene
CNC
$34.2B
$7.21M 0.63%
97,198
-93,409
-49% -$6.74M
2021 Q1
11 quarters
ELV icon
33
Elevance Health
ELV
$92.9B
$7.12M 0.63%
15,094
-6,600
-30% -$3.05M
2020 Q4
12 quarters
TSHA icon
34
Taysha Gene Therapies
TSHA
$1.18B
$6.69M 0.59%
3,780,714
+2,074,940
+122% +$4.14M
2023 Q3
1 quarter
GOSS icon
35
Gossamer Bio
GOSS
$53.6M
$5.87M 0.52%
80,409
+25,061
+45% +$1.48M
2021 Q3
9 quarters
AMRN icon
36
Amarin Corp
AMRN
$239M
$5.3M 0.47%
304,775
-116,819
-28% -$1.83M
2018 Q1
23 quarters
A icon
37
Agilent Technologies
A
$48.8B
$5.26M 0.46%
37,854
-3,971
-9% -$472K
2020 Q4
12 quarters
TSVT icon
38
DELISTED
2seventy bio
TSVT
$4.86M 0.43%
1,139,111
-314,267
-22% -$966K
2023 Q3
1 quarter
IMVT icon
39
Immunovant
IMVT
$5.52B
$4.79M 0.42%
+113,793
New +$4.19M
2023 Q4
0 quarters
STRO icon
40
Sutro Biopharma
STRO
$181M
$4.53M 0.4%
105,646
+28,682
+37% +$910K
2023 Q2
2 quarters
ICLR icon
41
Icon
ICLR
$13.1B
$4.36M 0.38%
15,417
-5,581
-27% -$1.44M
2021 Q3
9 quarters
NAMS icon
42
NewAmsterdam Pharma
NAMS
$2.37B
$4.18M 0.37%
374,404
-286,214
-43% -$2.62M
2023 Q1
3 quarters
MRUS icon
43
DELISTED
Merus
MRUS
$3.18M 0.28%
115,726
-18,284
-14% -$427K
2021 Q4
8 quarters
VRDN icon
44
Viridian Therapeutics
VRDN
$2.16B
$2.99M 0.26%
137,343
-305,927
-69% -$4.83M
2023 Q3
1 quarter
AVTR icon
45
Avantor
AVTR
$11.1B
$2.88M 0.25%
125,964
+41,469
+49% +$850K
2023 Q3
1 quarter
BHVN icon
46
Biohaven
BHVN
$1.63B
$2.86M 0.25%
66,898
-64,205
-49% -$2M
2022 Q4
4 quarters
IQV icon
47
IQVIA
IQV
$43.9B
$2.84M 0.25%
12,263
-10,778
-47% -$2.21M
2020 Q4
12 quarters
MCRB icon
48
Seres Therapeutics
MCRB
$24.7M
$2.45M 0.22%
87,677
-29,951
-25% -$786K
2022 Q3
5 quarters
MOH icon
49
Molina Healthcare
MOH
$10.8B
$2.21M 0.19%
6,117
-6,117
-50% -$2.16M
2023 Q2
2 quarters
IFRX icon
50
InflaRx
IFRX
$195M
$2.13M 0.19%
1,305,140
-432,404
-25% -$741K
2023 Q2
2 quarters
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Eversept Partners held 73 positions worth $1.14B, down 3.7% from $1.18B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Eversept Partners's Q4 2023 filing shows 4 new, 21 increased, 29 reduced and 16 closed positions. Its largest new stake was Immunogen Inc: 748,950 shares worth $22.2M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

  • Eversept Partners's largest Q4 2023 buy was Immunogen Inc: 748,950 shares worth $22.2M.
  • Eversept Partners added most to argenx in Q4 2023, an estimated $37.9M increase.
  • Eversept Partners's biggest Q4 2023 reduction was Danaher, cutting an estimated $16.2M.
  • Eversept Partners fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $23.8M.
  • Eversept Partners's ten largest holdings make up 62% of its $1.14B portfolio in Q4 2023.
  • Eversept Partners opened 4 new positions and closed 16 in Q4 2023.
  • Eversept Partners's portfolio value fell 3.7% quarter-over-quarter to $1.14B.

Based on Eversept Partners's 13F filing for Q4 2023, filed 14 Feb 2024.